Memorial Sloan Kettering Cancer Center’s Oric Pharmaceuticals ORIC Stock Holding History

Memorial Sloan Kettering Cancer Center’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$3.64M	Hold	602,272	–	–	14.84%	2
2023 Q2	$4.67M	Hold	602,272	–	–	14.75%	2
2023 Q1	$3.43M	Hold	602,272	–	–	10.53%	2
2022 Q4	$3.55M	Hold	602,272	–	–	11.7%	2
2022 Q3	$1.93M	Hold	602,272	–	–	6.55%	4
2022 Q2	$2.7M	Hold	602,272	–	–	8.92%	4
2022 Q1	$3.22M	Hold	602,272	–	–	3.72%	4
2021 Q4	$8.85M	Hold	602,272	–	–	5.56%	4
2021 Q3	$12.6M	Hold	602,272	–	–	7.85%	4
2021 Q2	$10.7M	Hold	602,272	–	–	6.97%	3
2021 Q1	$14.8M	Hold	602,272	–	–	9.09%	3
2020 Q4	$20.4M	Buy	+602,272	New	+$17.3M	8.63%	3

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Memorial Sloan Kettering Cancer Center's ORIC Position: Q3 2023 in Review

Memorial Sloan Kettering Cancer Center held its Oric Pharmaceuticals (ORIC) position steady in Q3 2023 at 602,272 shares worth $3.64M. The position accounts for 14.84% of the portfolio, ranked #2.

Memorial Sloan Kettering Cancer Center first reported a position in ORIC in Q4 2020 and has held it in 12 quarters since. The position peaked at $20.4M in Q4 2020. 90 funds tracked by Wall St. Rank hold ORIC as of Q3 2023.

Memorial Sloan Kettering Cancer Center held 602,272 shares of Oric Pharmaceuticals worth $3.64M as of Q3 2023.
Memorial Sloan Kettering Cancer Center left its Oric Pharmaceuticals share count unchanged in Q3 2023.
Oric Pharmaceuticals made up 14.84% of Memorial Sloan Kettering Cancer Center's portfolio in Q3 2023, its #2 holding.
Memorial Sloan Kettering Cancer Center first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
Memorial Sloan Kettering Cancer Center's Oric Pharmaceuticals position peaked at $20.4M in Q4 2020.
90 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2023.

Based on Memorial Sloan Kettering Cancer Center's 13F filing for Q3 2023, filed 14 Nov 2023.